AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
$1.22B |
| 2 |
NVIDIA
NVDA
|
$535M |
| 3 |
Sherwin-Williams
SHW
|
$400M |
| 4 |
lululemon athletica
LULU
|
$386M |
| 5 |
Veralto
VLTO
|
$377M |
Top Sells
| 1 |
Microsoft
MSFT
|
$867M |
| 2 |
Alphabet (Google) Class C
GOOG
|
$488M |
| 3 |
Zoetis
ZTS
|
$380M |
| 4 |
PTC
PTC
|
$329M |
| 5 |
Edwards Lifesciences
EW
|
$279M |
Sector Composition
| 1 | Technology | 27.64% |
| 2 | Healthcare | 17.41% |
| 3 | Financials | 11.02% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAIN
3126
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $51.1K | ﹤0.01% |
42,580
| – | – |
|
3127
CorMedix
CRMD
$956M
| $50.8K | ﹤0.01% |
13,500
| – | – |
|
3128
Acacia Research
ACTG
$322M
| $49.4K | ﹤0.01% |
+12,600
| New | +$49.4K |
|
3129
Nautilus Biotechnolgy
NAUT
$82.3M
| $49.2K | ﹤0.01% |
16,470
-110
| -0.7% | -$329 |
|
3130
Information Services Group
III
$255M
| $48.9K | ﹤0.01% |
+10,390
| New | +$48.9K |
|
3131
Assertio
ASRT
$77.7M
| $48.5K | ﹤0.01% |
45,310
| – | – |
|
3132
Purple Innovation
PRPL
$119M
| $47.8K | ﹤0.01% |
46,400
-8,040
| -15% | -$8.28K |
|
3133
CXApp
CXAI
$15.1M
| $46K | ﹤0.01% |
35,630
+4,070
| +13% | +$5.25K |
|
3134
Cadiz
CDZI
$294M
| $45.6K | ﹤0.01% |
16,290
-3,190
| -16% | -$8.93K |
|
3135
MarketWise
MKTW
$49.9M
| $44.7K | ﹤0.01% |
819
+149
| +22% | +$8.13K |
|
3136
Accuray
ARAY
$170M
| $43.9K | ﹤0.01% |
15,520
| – | – |
|
|
KLRS
3137
Kalaris Therapeutics, Inc. Common Stock
KLRS
$87.2M
| $43.8K | ﹤0.01% |
2,801
-272
| -9% | -$4.25K |
|
3138
FiscalNote
NOTE
$57.5M
| $43.2K | ﹤0.01% |
3,155
| – | – |
|
3139
Urban One Class A
UONE
$74.4M
| $42.6K | ﹤0.01% |
10,580
-250
| -2% | -$1.01K |
|
3140
Veritone
VERI
$153M
| $42.6K | ﹤0.01% |
23,530
+3,550
| +18% | +$6.43K |
|
|
SRTA
3141
Strata Critical Medical, Inc. Class A Common Stock
SRTA
$341M
| $42.1K | ﹤0.01% |
11,940
| – | – |
|
3142
Protalix BioTherapeutics
PLX
$127M
| $41.7K | ﹤0.01% |
23,400
| – | – |
|
|
EVA
3143
DELISTED
Enviva Inc.
EVA
| $41.5K | ﹤0.01% |
41,680
-12,420
| -23% | -$12.4K |
|
|
NXDR
3144
Nextdoor Holdings
NXDR
$794M
| $41K | ﹤0.01% |
21,700
| – | – |
|
3145
Babcock & Wilcox
BW
$221M
| $40.1K | ﹤0.01% |
27,470
| – | – |
|
|
MOND
3146
DELISTED
Mondee Holdings, Inc. Class A Common Stock
MOND
| $39.2K | ﹤0.01% |
14,190
-640
| -4% | -$1.77K |
|
|
DADA
3147
DELISTED
Dada Nexus
DADA
| $38.9K | ﹤0.01% |
11,727
| – | – |
|
3148
Century Therapeutics
IPSC
$41.4M
| $38.4K | ﹤0.01% |
11,580
-1,100
| -9% | -$3.65K |
|
3149
X4 Pharmaceuticals
XFOR
$81.7M
| $38.3K | ﹤0.01% |
1,523
| – | – |
|
3150
Omeros
OMER
$284M
| $38.3K | ﹤0.01% |
11,700
| – | – |
|